Unbound MEDLINE

Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.

Abstract

In this 12-week, randomized, double-blind, placebo-controlled trial, the efficacy and safety of transglucosidase (TGD) were compared with placebo in patients with type 2 diabetes mellitus (T2DM). At 12 weeks, TGD 300 mg/day and TGD 900 mg/day significantly reduced HbA1c (0.18 and 0.21%) and insulin concentration (19.4 and 25.0 pmol/l), respectively, vs. placebo. TGD 300 mg/day and TGD 900 mg/day also significantly reduced low-density lipoprotein cholesterol (0.22 and 0.17 mmol/l, respectively). TGD 900 mg/day significantly reduced triglyceride by 0.24 mmol/l and diastolic blood pressure by 8 mmHg. Placebo was associated with a significant increase from baseline in body mass index, alanine aminotransferase and aspartate aminotransferase (0.17 kg/m(2) , 3 and 2 U/l, respectively), whereas TGD was not. TGD 300 mg/day significantly increased high-molecular-weight adiponectin by 0.6 µg/ml. Adverse events did not differ significantly between the groups. TGD resulted in lowering of HbA1c and blood insulin level and improvements in metabolic and cardiovascular risk factors in T2DM.

Links

  • Publisher Full Text
  • Authors

    Sasaki M, Imaeda K, Okayama N, Mizuno T, Kataoka H, Kamiya T, Kubota E, Ogasawara N, Funaki Y, Mizuno M, Iida A, Goto C, Koikeda S, Kasugai K, Joh T

    Source

    Diabetes, obesity & metabolism 14:4 2012 Apr pg 379-82

    MeSH

    Adiponectin
    Alanine Transaminase
    Aspartate Aminotransferases
    Biological Markers
    Blood Glucose
    Blood Pressure
    Body Mass Index
    Cardiovascular Diseases
    Cholesterol, LDL
    Diabetes Mellitus, Type 2
    Double-Blind Method
    Female
    Glucosyltransferases
    Hemoglobin A, Glycosylated
    Humans
    Hypoglycemic Agents
    Insulin
    Liver
    Male
    Middle Aged
    Risk Factors
    Triglycerides

    Pub Type(s)

    Comparative Study
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    22098444